Biomarkers such as TP53 mutations, VEGF expression, and TUBB3 levels, as mentioned earlier, have been linked to increased resistance to therapy, poor prognosis, and aggressive tumor behavior in NSCLC [66,67,68,69,70]. Here, TUBB3 is linked to neoplasm.